Nick A. Hanania, MD and Barbara P. Yawn, MD, MSc, FAAFP
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
Nick A. Hanania, MD
Associate Professor of Medicine
Director, Airways Clinical Research Center
Pulmonary, Critical Care, and Sleep Medicine
Baylor College of Medicine
Barbara P. Yawn, MD, MSc, FAAFP
Department of Family and Community Health
University of Minnesota
This program is designed to provide primary care providers (PCPs) with education on the assessment of asthma in patients—with an emphasis on recognizing severe asthma—when specialist referral is warranted, and an overview of available advanced treatments for severe asthma. Despite the clear need for comprehensive and intensive management, PCPs are challenged to identify, assess, and coordinate treatment for patients with severe asthma. A pulmonologist and a primary care physician who are experts in asthma management provide practical recommendations for PCPs on how to best assess the severity of a patient’s asthma and evaluate the causes of poor asthma control. Faculty also update PCPs on the quickly evolving treatment landscape and on recommendations on how to monitor for disease progression and treatment responses. Educating patients about their disease, routine use of asthma action plans, and treatment options are other topics important to time-limited PCPs also covered in this program.
The educational design of this activity addresses the needs of primary care providers (PCPs) involved in the assessment, referral, and multidisciplinary management of severe asthma.
After completing this activity, the participant should be better able to:
- Identify patients with asthma who should be referred for specialist follow-up based on ongoing symptoms, exacerbation history, and treatment responses
- Discuss biologic options that have been approved by the US Food and Drug Administration for the treatment of severe asthma
- Coordinate the management of patients with severe asthma that requires multidisciplinary care to maximize symptom control, reduce exacerbation risks, and minimize medication-related toxicities
- Educate patients with severe asthma about disease-related risks, long-term treatment options, and information related to adherence and self-management
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) which includes 0.1 hour(s) of pharmacology.
Activity ID #2926E
This activity was planned in accordance with AANP CE Standards and Policies.
Term of Offering
This activity was released on September 30, 2019 and is valid for one year. Requests for credit must be made no later than September 30, 2020.
Disclosure of Conflicts of Interest
Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Nick A. Hanania, MD: Advisory Board: AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Mylan N.V., Novartis AG, sanofi-aventis U.S. LLC; Honoraria: AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Mylan N.V., Novartis AG, sanofi-aventis U.S. LLC; Research Grants: AztraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc
Barbara P. Yawn, MD, MSc, FAAFP: Consultant: AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Ashley Marostica, RN, MSN: Nothing to disclose
Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Julia Muino: Nothing to disclose
Jim Kappler, PhD: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Instructions to Receive Credit
In order to receive credit, participants must complete the preassessment questions, view the activity in its entirety, and complete the posttest and program evaluation. Participants must also score at least 75% on the posttest. You will receive a digital copy of your credit certificate at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.